Andrew HunzekerHesed left high-profile consumer software roles to become the first employee at 10x Science, a startup creating AI-driven tools for proteomics and drug discovery. He highlights the challenge of early-stage problem discovery over scaling and the impact of working closely with founders focused on foundational AI principles.
- Andrew HunzekerHesed transitioned from leading consumer software projects to life sciences AI startup.
- Joined 10x Science as Employee #1, quickly delivering solutions for drug discovery challenges.
- 10x Science is advancing from exploratory research to deploying tools for paying customers.
What happened
Andrew HunzekerHesed brought extensive experience from consumer-scale tech companies to join 10x Science as its founding engineer. After meeting the founders and engaging in a demanding multi-day work trial, he was drawn by their principled approach to AI and math rather than typical commercial pitches. This led to him becoming employee number one at the Y Combinator-backed startup.
In his first week, Andrew helped design and build a solution for a leading pharmaceutical firm on a problem new to the team, demonstrating the startup’s rapid innovation pace. This initial tool has since become a foundational part of 10x Science’s product suite, underscoring his early impact.
Why it matters
Andrew emphasizes that joining early-stage companies is about tackling the unknown: defining the actual product, not just scaling existing technology. This mindset shift from large-scale engineering roles to foundational problem-solving reflects the unique challenges and opportunities in startups focused on AI-driven life sciences.
The startup’s mission to develop AI-native software for complex scientific data significantly advances drug discovery and proteomics, areas critical to healthcare innovation. By bridging AI principles with domain-specific challenges, 10x Science aims to transform how scientific analysis is conducted, moving beyond generic AI applications.
What to watch next
10x Science is transitioning from exploratory research to solidifying features for commercial customers, signaling a pivotal growth stage. Observers should monitor how the company scales its foundational tools while maintaining the agility and problem-first approach highlighted by Andrew’s role.
With a focus on simplicity in tooling and flexibility across AI models, 10x Science’s approach to product development could influence evolving best practices for AI integration in scientific research software. Andrew’s perspective on avoiding restrictive AI frameworks while iterating rapidly could become a guiding model.